ArticleVaccines2025
Comparison of Yeast and CHO Cell-Derived Hepatitis B Vaccines and Influencing Factors in Vaccine-Naïve Adults in China: Insights for Personalized Immunization Strategies.
Article in Vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundVarious factors influence the immunologic responses to HBV vaccines in adults, including unchangeable individual characteristics. Personalized vaccination regimens accounting for host factors can enhance immune efficiency, particularly for adults at higher risk.
methodsIn this two-center controlled trial, HBV vaccine-naïve participants aged 25-55 were randomly administered the two types of HBV vaccines (yeast cell-derived (YDV) or Chinese hamster ovary (CHO) cell-derived) at 0-1-6 months. Antibody titers were measured eight weeks after the final dose.
resultsOverall, 289 participants with YDV and 293 participants with CHO completed the three-dose series and antibody testing. The seroprotection rates (SPRs) were comparable (97.23% vs. 98.98%;
conclusionThe CHO regimen may be advantageous for HBV vaccine-naïve adults aged 25-55 with BMI ≥ 25 or those who smoke or drink, in terms of immunogenicity and durability, providing insights for personalized immunization strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.